Co-sponsored by The Technology Collaborative and Carnegie Mellon University, this robotics cluster meeting will feature some of the leading minds in robotics in our region.
- Welcome and Introductions, David Ruppersberger,President & CEO, TTC
- Opening Remarks, Jared Cohon, President, CMU
- Regional Companies Update, Patti Rote
- Featured Company Presentation, Aldo Zini, President & CEO, Aethon
- CMU Robotics Institute Update, Matt Mason, Director
- New Masters in Robotics Systems, Hagen Schempf, Principal Systems Scientist
- PA DCED Center for Trade Development, Peter O’Neill, Executive Director
- Results of Study on Robotics Prototyping, Bill Thomasmeyer
- National Initiatives Update, Bill Thomasmeyer
- Congressional Caucus
- Robotics Technology Consortium
- National Road Map & OSTP Federal Funding Initiative
- National Robotics Week
- Boston Robotics Cluster Update Elizabeth Newstadt (Invited)
- Upcoming Events Patti Rote
Last summer, after finding out about Wombat Security Technologies and its Phil training game, a highly successful interactive module that teaches people to recognize fraudulent URLs used in phishing attacks, Transplace purchased a one-year license for the product to train its employees. A year into using the Anti-Phishing Phil game, the company could not have been more pleased with the product. Today Transplace has announced that it is renewing its license for Phil and also purchasing a license for Wombat’s twin training game, Anti-Phishing Phyllis, a complementary module that teaches users to recognize a wide range of fraudulent emails. By licensing both products, Transplace is diversifying the training content it offers its employees and further strengthening the readiness of its workforce.
Studies have shown that conventional anti-phishing training methods are ineffective. In contrast, Wombat’s interactive training draws on learning science and gaming principles, resulting in training that is engaging, effective, and educational for employees and customers. The result is that people are better at retaining what they have learned and applying it when a real phishing attack occurs. Wombat’s training products have been featured in prestigious publications such as Scientific American for their novelty and effectiveness.
The interactive nature of Wombat Security Technologies’ games provides for unique teachable moments, where users are provided with immediate feedback on decisions they make, and mistakes are turned into learning opportunities. The use of fun characters and the story-based element of the games help further reinforce learning. The games are organized as a sequence of rounds, with each round introducing the user to new concepts of increasing difficulty. At the end of each round, a feedback module helps users reflect on the new knowledge they have learned.
“We are pleased to see Transplace renew their license of Anti-Phishing Phil for another year. Our new game Anti-Phishing Phyllis is a natural complement to Phil, and the combined training offers a highly effective suite of anti-phishing training for Transplace to educate their employees. By using Wombat’s interactive training, Transplace has renewed their commitment to being at the forefront of combating phishing attacks,” said Dr. Norman Sadeh, CEO of Wombat Security Technologies.
The games have been designed to be easy to translate into other languages and to customize. The training is easy to deploy by both small and large organizations and comes with extensive tracking and reporting functionality, enabling organizations to closely monitor their training campaigns. The training is also SCORM and 508 compliant and can be readily integrated into a Learning Management System.
For more information about Wombat Security, click here.
- Biogen Idec expects to initiate Phase 3 program in the first half of 2011 Equity investment and potential license payments of $345 million
Biogen Idec (NASDAQ: BIIB) and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and potentially other indications.
KNS-760704 is a novel oral neuroprotective therapy under development. In a Phase 2 study of ALS patients conducted by Knopp, the compound achieved its primary endpoint evaluating safety and tolerability and showed favorable dose-related effects in preserving motor function and extending survival. KNS-760704 has received orphan drug designation from the U.S. Food and Drug Administration and the European Commission for the treatment of patients with ALS, as well as Fast Track designation from the FDA. Biogen Idec expects to initiate a Phase 3 program of the compound in the first half of 2011.
Under the terms of the agreement, Biogen Idec will lead the development of KNS-760704 for ALS and its potential commercialization in global markets, with Knopp providing development support and conducting certain U.S. commercialization activities under the direction of Biogen Idec. As part of the transaction, Biogen Idec will purchase $60 million of Knopp stock, provide an up-front payment of $20 million and additional payments of up to $265 million based on the achievement of development, regulatory, and sales milestones. Biogen Idec will also pay tiered, double-digit royalties to Knopp on worldwide sales.
“We are very pleased to enter into this agreement with Biogen Idec, a world leader in neurology drug development and commercialization,” said Michael Bozik, M.D., president and CEO of Knopp, a privately held, Pittsburgh-based biopharmaceutical company. “Biogen Idec’s proven track record of delivering innovative medicines for diseases with high unmet needs makes it the ideal partner to advance KNS-760704 in ALS.”
“We are excited to begin this new collaboration with Knopp on KNS-760704, a potential treatment for ALS with promising Phase 2 data,” said George Scangos, Ph.D., CEO of Biogen Idec. “ALS is a devastating disorder and, with only one approved therapy, there is a tremendous need to provide more therapeutic options for patients. This disease is a natural fit for Biogen Idec, given our global capabilities in neurology, and we look forward to beginning a Phase 3 program.”
Knopp has completed a two-part Phase 2 study that assessed the effects of KNS-760704 in the same subjects over two randomized, double-blind treatment periods separated by a one-month washout. These Phase 2 data were presented at the 20th International Symposium on ALS/MND in Berlin in December 2009. In Part 1 of the study, 102 subjects received daily doses of 50 mg, 150 mg, or 300 mg of KNS-760704 or placebo for 12 weeks. KNS-760704 showed a dose- dependent trend in slowing the rate of disease progression, as measured by the difference in slopes of the ALS Functional Rating Scale-Revised (ALSFRS-R) across treatment groups, with the greatest benefit observed in the 300 mg dose group.
In Part 2 of the study, 92 subjects were re-randomized to receive daily doses of 50 mg or 300 mg of KNS-760704 for 24 weeks. In addition to results again suggesting a dose-dependent trend in slowing the rate of disease progression as measured by the ALSFRS-R, there was also a trend toward a survival benefit in the 300 mg group compared with the 50 mg group. In an exploratory test comparing subject rankings on the basis of mortality and functional outcomes, subjects in the 300 mg group had a significantly improved outcome compared with the 50 mg group.
KNS-760704 was generally well tolerated. There were no per-treatment group differences in the frequency of adverse events or serious adverse events reported in the Phase 2 trial. The most common adverse events reported more frequently than in placebo subjects were fall, nausea, and joint pain. Some cases of neutropenia were observed, which resolved when therapy was discontinued and generally did not recur when therapy was reinitiated.
- Western Pennsylvania Data Center Among the First in EPA’s Registry of More than 11,000
- Commercial Facilities to Receive Distinguished Recognition
BNY Mellon’s Northpointe Data Center located in southwestern Pennsylvania has received the U.S. Environmental Protection Agency’s (EPA) coveted ENERGY STAR® award. Northpointe is currently among the first data centers listed in the EPA’s entire 11,000-plus registry of commercial properties to meet the stringent energy-efficiency specifications designed to promote superior energy use and performance, and prevent greenhouse gas emissions. BNY Mellon is a global financial services firm.
Locally, the company employs more than 7,000 people, including more than 1,200 technology workers.
To view the full press release, click here.